BCL2 and cancer: The epigenetic changes often prime the cells to be more susceptible for additional cytotoxic treatments and may reverse acquired resistance.166,171–173 Most DNMTs impact the BCL2 proteins by means of upregulation of the BH3-only protein NOXA, as shown for several cancer types.174–176 Pro-apoptotic BMF and anti-apoptotic BCL2A1 are also regulated through HDAC inhibitors.177 The expression of MCL1 is additionally regulated by methylation status, which correlates with cisplatin sensitivity in osteosarcoma.178